Search Results

You are looking at 1 - 10 of 481 items for :

  • "neoplasms" x
  • Refine by Access: All x
Clear All
Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes

(NCCN Guidelines) for Uterine Neoplasms describe malignant epithelial carcinomas and uterine sarcomas; each of these major categories contains specific histologic groups that require different management (see UN-1, page 250). This excerpt of the NCCN

Full access

Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A. M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar

Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPN). The prevalence of MF, ET

Full access

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

Uterine Neoplasms Adenocarcinoma of the endometrium (also known as endometrial cancer , or more broadly as uterine cancer or carcinoma of the uterine corpus ) is the most common malignancy of the female genital tract in the United States. It is

Full access

Ruben A. Mesa

Inaugural guidelines for the treatment of myeloproliferative neoplasms (MPNs) were unveiled at the NCCN 22nd Annual Conference. The first set of these guidelines discusses treatment recommendations only for myelofibrosis (MF). In 2017, guidelines

Full access

Brady L. Stein, Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, Daniel A. Pollyea, Bart Scott, Martha Wadleigh, Ross Levine, Rami Komrokji, Rebecca Klisovic, Krishna Gundabolu, Patricia Kropf, Meir Wetzler, Stephen T. Oh, Raul Ribeiro, Rita Paschal, Sanjay Mohan, Nikolai Podoltsev, Josef Prchal, Moshe Talpaz, David Snyder, Srdan Verstovsek, and Ruben A. Mesa

The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), were initially described in the medical literature in 1879, 1892, and

Full access

Chunkit Fung, Sophie D. Fossa, Clair J. Beard, and Lois B. Travis

relative survival rates of men with TC are both 95%. 2 , 3 This success results in not only an average gain of an additional 37 years of life 4 but also the emergence of considerable morbidities. These include second malignant neoplasms (SMNs), which have

Full access

Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu Reddy, Lindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar

Myeloproliferative Neoplasms Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Myeloproliferative Neoplasms NCCN Guidelines Insights : Myeloproliferative Neoplasms, Version 2.2018 Version 2.2018 © National

Full access

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng

the express written permission of the NCCN © 2009. Disclosures for the NCCN Uterine Neoplasms Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry

Full access

Howard A. Chang, Saro H. Armenian, and Thanh H. Dellinger

neoplasms is therefore paramount to providing clinicians with early intervention opportunities in this high-risk population. The primary goal of this review is to summarize the current literature describing female lower genital tract neoplasms (dysplasias

Full access

Amy E. DeZern and Peter L. Greenberg

, two separate classification publications have been reported—the 5th edition of the WHO classification of diseases 3 and the newer ICC of myeloid neoplasms. 4 Although an update to the classification of MDS was warranted, given advances in the